

# Use of erythropoietin for anaemia management, clearance of low and middle molecular weight uraemic toxins, quality of life and cost effectiveness of mid-dilution on-line haemodiafiltration compared to conventional low flux haemodialysis

<b>Submission date</b> 29/09/2006	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
<b>Registration date</b> 29/09/2006	<b>Overall study status</b> Completed	<input type="checkbox"/> Protocol
<b>Last Edited</b> 17/05/2017	<b>Condition category</b> Haematological Disorders	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr A Chesser

**Contact details**  
Consultant Nephrologist  
Renal Office  
Royal London Hospital  
Whitechapel  
London  
United Kingdom  
E1 1BB  
+44 (0)20 7377 7366  
alistair.chesser@bartsandthelondon.nhs.uk

## Additional identifiers

**Protocol serial number**

N0205168926

## Study information

**Scientific Title**

Use of erythropoietin for anaemia management, clearance of low and middle molecular weight uraemic toxins, quality of life and cost effectiveness of mid-dilution on-line haemodiafiltration compared to conventional low flux haemodialysis

**Study objectives**

To quantify the effect of on-line mid-dilution haemodiafiltration on the use of erythropoietin for anaemia management in patients with end-stage renal disease compared to the technique of conventional haemodialysis.

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Not provided at time of registration

**Study design**

Randomised controlled trial

**Primary study design**

Interventional

**Study type(s)**

Treatment

**Health condition(s) or problem(s) studied**

Anaemia

**Interventions**

Not provided at time of registration

**Intervention Type**

Drug

**Phase**

Not Applicable

**Drug/device/biological/vaccine name(s)**

Erythropoietin

**Primary outcome(s)**

Control of haemoglobin and use of erythropoietin

**Key secondary outcome(s)**

Not provided at time of registration

**Completion date**

31/07/2007

## Eligibility

**Key inclusion criteria**

Not provided at time of registration

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Not Specified

**Sex**

Not Specified

**Key exclusion criteria**

Not provided at time of registration

**Date of first enrolment**

27/07/2005

**Date of final enrolment**

31/07/2007

## Locations

**Countries of recruitment**

United Kingdom

England

**Study participating centre**

Royal London Hospital

London

United Kingdom

E1 1BB

## Sponsor information

**Organisation**

Record Provided by the NHSTCT Register - 2006 Update - Department of Health (UK)

**Funder(s)****Funder type**

Government

**Funder Name**

Barts and The London NHS Trust (UK)

**Funder Name**

NHS R&D Support Funding (UK)

**Results and Publications**

**Individual participant data (IPD) sharing plan**

**IPD sharing plan summary**

Not provided at time of registration